Results 161 to 170 of about 670,718 (407)

Impact of Individual Risk Assessment on Prostate Cancer Diagnosis [PDF]

, 2012
Current prostate-specific antigen screening practice leads to two important unwanted side effects; first of all screening induces many unnecessary prostate biopsies and secondly it leads to overdiagnosis and overtreatment of prostate cancer.
Vugt, H.A. (Heidi) van
core  

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation

Advanced Science, EarlyView.
The study deciphers the landscapes of lineage‐related transcription factors in prostatic adenocarcinoma and neuroendocrine prostate cancer using an innovative approach. These findings, validated across cohorts, highlight TFs' roles in cell development and offer novel therapeutic targets.
Yu Wang, Hui Xue, Xiaohui Zhu, Dong Lin, Zheng Chen, Xin Dong, Junru Chen, Mingchen Shi, Yuchao Ni, Jonathan Cao, Rebecca Wu, Connie Kang, Xinyao Pang, Francesco Crea, Yen‐Yi Lin, Colin C. Collins, Martin E. Gleave, Abhijit Parolia, Arul Chinnaiyan, Christopher J. Ong, Yuzhuo Wang   +20 more
wiley   +1 more source

Race‐specific prostate cancer outcomes in a cohort of low and favorable‐intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017

Cancer Medicine, Volume 11, Issue 24, Page 4756-4766, December 2022., 2022
This study explored whether differences in long‐term oncological outcomes exist for African American compared to Caucasian American men diagnosed with low risk or favorable‐intermediate risk prostate cancer and treated with external beam radiation therapy, in equal access health care settings.
Sean P. Stroup, Audry H. Robertson, Kayla C. Onofaro, Michael G. Santomauro, Nicholas R. Rocco, Huai‐ching Kuo, Avinash R. Chaurasia, Samantha Streicher, Darryl Nousome, Timothy C. Brand, John E. Musser, Christopher R. Porter, Inger L. Rosner, Gregory T. Chesnut, Anthony D'Amico, Grace Lu‐Yao, Jennifer Cullen   +16 more
wiley   +1 more source

GRP78 Nanobody‐Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy

Advanced Science, EarlyView.
A GRP78 nanobody‐directed immunotoxin suppresses cancer progression and metastasis by enhancing antitumor immunity via STING pathway activation, offering a pan‐cancer‐targeted approach and immunotherapy combination strategy. Abstract The lack of targetable antigens poses a significant challenge in developing effective cancer‐targeted therapies.
Huifang Wang, Runhua Zhou, Chengchao Xu, Lingyun Dai, Rui Hou, Liuhai Zheng, Chunjin Fu, Guangwei Shi, Jingwei Wang, Yang Li, Jinpeng Cen, Xiaolong Xu, Le Yu, Yilei Li, Jigang Wang, Qingfeng Du, Zhijie Li   +16 more
wiley   +1 more source

Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology

Cancer Medicine, Volume 11, Issue 24, Page 4830-4837, December 2022., 2022
minimal residual disease assessment in post surgery patients with papillary thyroid cancer through CTCs‐based cytology Abstract The overall estimated risk of recurrence after an apparently complete thyroid cancer resection ranges from <1% to 55%, and the high‐quality pathology report is crucial for proper risk stratification.
Nadia Innaro, Rita Gervasi, Teresa Ferrazzo, Nastassia C. Garo, Lucia S. Curto, Annamaria Lavecchia, Isabella Aquila, Giuseppe Donato, Natalia Malara   +8 more
wiley   +1 more source

dyAb: Flow Matching for Flexible Antibody Design with AlphaFold-driven Pre-binding Antigen [PDF]

arXiv
The development of therapeutic antibodies heavily relies on accurate predictions of how antigens will interact with antibodies. Existing computational methods in antibody design often overlook crucial conformational changes that antigens undergo during the binding process, significantly impacting the reliability of the resulting antibodies.
arxiv  

Discordance between concentrations of prostate-specific antigen and acid phosphatase in serum of patients with adenocarcinoma of the prostate. [PDF]

, 1988
ThomasM Beaver, Adam Schultz, Lore Fink, C. Andersen, Rafe Donohue   +4 more
openalex   +1 more source

Reactivity of 77 Antibodies to Prostate-Specific Antigen with Isoenzymes and Complexes of Prostate-Specific Antigen

Tumor Biology, 1999
Seventy-seven antibodies submitted to the ISOBM TD-3 PSA Workshop (TD-3.1 and TD-3.2) were characterized by measuring their reactivity with isoenzymes of free prostate-specific antigen (PSA), PSA complexed to alpha1-antichymotrypsin (PSA-ACT) and alpha1-proteinase inhibitor (PSA-API).
Wan-Ming Zhang, Elisabeth Paus, Jari Leinonen, U.-H. Stenman   +3 more
openaire   +3 more sources

Machine Learning‐Based Radiomics in Malignancy Prediction of Pancreatic Cystic Lesions: Evidence from Cyst Fluid Multi‐Omics

Advanced Science, EarlyView.
This study develops noninvasive clinical‐radiomic models using preoperative CT images to predict the malignant potential of pancreatic cystic lesions. It demonstrates the models' high accuracy across various datasets, with AUCs exceeding 0.92. Additionally, multi‐omics analyses uncover key biological mechanisms, including secretion function and lipid ...
Sihang Cheng, Ge Hu, Shenbo Zhang, Rui Lv, Limeng Sun, Zhe Zhang, Zhengyu Jin, Yanyan Wu, Chen Huang, Lu Ye, Zhe‐Sheng Chen, Yunlu Feng, Aiming Yang, Zhiwei Wang, Huadan Xue   +14 more
wiley   +1 more source

TGIF1 overexpression promotes glioma progression and worsens patient prognosis

Cancer Medicine, Volume 11, Issue 24, Page 5113-5128, December 2022., 2022
This study is the first to comprehensively analyze and reveal TGIF1, as a new oncogene, is closely related to the malignancy‐related phenotype of glioma, and that TGIF1 could be an independent risk factor for poor prognosis of glioma, which is expected to become a new target for individualized treatment of glioma patients.
Baoya Wang, Qiong Ma, Xuelin Wang, Kunshan Guo, Zhendong Liu, Gang Li   +5 more
wiley   +1 more source